1 Ceramide, generated by the hydrolysis of sphingomyelin, mediates the actions of several cytokines such as tumour necrosis factor-a (TNF-a) interferon-g and interleukin-1b (IL-1b), including their inhibitory e ect on tumour proliferation. We have evaluated the role of ceramide in the proliferation of prostate cancer by using the human prostate adenocarcinoma LNCaP cell line. 2 Treatment of LNCaP cells with neutral or acidic sphingomyelinase or addition of C8-or C2-ceramide, two cell permeable analogues of endogenous ceramide, induced a profound inhibition of cell proliferation. This e ect appeared after 24 h, was still present after 72 h of exposure to the drugs and exhibited concentration-dependency (10 ± 200 and 5 ± 200 mU ml 71 for neutral and acidic sphingomyelinase, respectively, and 1 ± 25 mM for C8-ceramide). 3 The inhibitory e ect on cell growth caused by neutral sphingomyelinase and ceramides was rapidly reversible as LNCaP cells rapidly regained their previous proliferation rate following withdrawal of the treatment. 4 IL-1b produced profound inhibition of LNCaP cell proliferation and caused enhanced ceramide formation. 5 No clear features of apoptotic cell death were detectable by either oligonucleosome formation, cyto¯uorimetric analysis or nuclear staining following exposure of LNCaP cells to neutral sphingomyelinase, ceramide or IL-1b. However, clear changes in LNCaP cell cycle distribution were detectable following these treatments. In contrast, treatment with acidic sphingomyelinase or TNF-a induced apoptotic death detectable by¯ow cytometric analysis and bisbenzimide staining. 6 In conclusion, our data demonstrate that preferential activation of distinct enzymatic pathways by cytokines may lead to di erent outcomes in the viability of LNCaP cells.